# Trade Mark Journal No.2026/007 13 February 2026

## WO0000001899667 (5)

Office of origin: United States of America

Date of International Registration:19 December 2025
Date of designation in the UK: 19 December 2025

International priority date claimed: 31 July 2025 (United States of America) (99312521)

Class 5
  Pharmaceuticals and pharmaceutical preparations for use in the treatment of central nervous system diseases and disorders; pharmaceuticals and pharmaceutical preparations for use in the treatment of neurodevelopmental diseases and disorders; pharmaceuticals and pharmaceutical preparations for use in the treatment of rett syndrome diseases and disorders; pharmaceuticals and pharmaceutical preparations for use in intrathecally administered gene therapy treatments.

Taysha Gene Therapies, Inc.

Representative: John L. DuPre' Hamilton, Brook, Smith & Reynolds, P.C., 155 Seaport Blvd., BostonMA 02210, UNITED STATES OF AMERICA